Literature DB >> 1825315

Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.

S C Hadler1, F N Judson, P M O'Malley, N L Altman, K Penley, S Buchbinder, C A Schable, P J Coleman, D N Ostrow, D P Francis.   

Abstract

To investigate the effect of human immunodeficiency virus type 1 (HIV-1) infection on subsequent hepatitis B virus (HBV) infection, HIV antibody was sought in homosexual men who developed HBV infection during a hepatitis B vaccine trial. Among 134 unvaccinated HIV-1-negative men, 7% became HBV carriers, 64% had viremia, and 42% had clinical illness. Among vaccinated HIV-1-negative men, HBV infection severity decreased with number of vaccine doses administered. When adjusted for prior hepatitis B vaccination status, persons with HIV-1 infection preceding HBV infection had a significantly higher risk of developing HBV carriage, viremia, prolonged ALT elevation, and clinical illness. Among HIV-1-infected men, the risk of HBV carriage was increased in unvaccinated persons (21%) and those who failed to respond to vaccination (31%) and further increased in those who received vaccine doses at the time they developed new HBV infection (56%-80%), suggesting inactivated hepatitis B vaccine may temporarily impair the immune response to HBV infection in HIV-1-infected persons. HIV-1 infection was also associated with reduced alanine aminotransferase elevations during the first 36 months of follow-up of men who became HBV carriers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825315     DOI: 10.1093/infdis/163.3.454

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  Sexually transmitted hepatitis: a review.

Authors:  R J Gilson
Journal:  Genitourin Med       Date:  1992-04

2.  Management of HIV/HBV coinfection.

Authors:  Andy O Miller
Journal:  MedGenMed       Date:  2006-02-07

Review 3.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

4.  Identifying a hepatitis B outbreak by molecular surveillance: a case study.

Authors:  N Fisker; N L T Carlsen; H J Kolmos; L Tønning-Sørensen; A Høst; P B Christensen
Journal:  BMJ       Date:  2006-02-11

Review 5.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

6.  Prevalence and incidence of hepatitis B virus infection in STD clinic attendees in Pune, India.

Authors:  A Risbud; S Mehendale; S Basu; S Kulkarni; A Walimbe; V Arankalle; R Gangakhedkar; A Divekar; R Bollinger; D Gadkari; R Paranjape
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

7.  Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.

Authors:  Kentaro Matsuura; Yasuhito Tanaka; Shuhei Hige; Gotaro Yamada; Yoshikazu Murawaki; Masafumi Komatsu; Tomoyuki Kuramitsu; Sumio Kawata; Eiji Tanaka; Namiki Izumi; Chiaki Okuse; Shinichi Kakumu; Takeshi Okanoue; Keisuke Hino; Yoichi Hiasa; Michio Sata; Tatsuji Maeshiro; Fuminaka Sugauchi; Shunsuke Nojiri; Takashi Joh; Yuzo Miyakawa; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

Review 8.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

9.  Acute Hepatitis B and Acute HIV Coinfection in an Adult Patient: A Rare Case Report.

Authors:  Raghav Bansal; Maurice Policar; Chinar Mehta
Journal:  Case Rep Med       Date:  2010-11-07

Review 10.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.